PETMED EXPRESS INC Annual Report - How They Did This Year

I’ve put together this guide to help you understand how PetMed Express (PetMeds) performed over the past year. My goal is to explain the "corporate speak" so you can decide if this company fits your portfolio.

1. What does this company do?

PetMeds is a leading online pet pharmacy. They sell prescription and non-prescription medications, health products, and supplies directly to pet owners. The company is currently shifting from one-time sales to an "Autoship" subscription service. This move aims to keep customers longer and create predictable, recurring income, similar to other major pet e-commerce brands.

2. Financial Performance: The Bottom Line

The past year was difficult as PetMeds paid for its business transformation.

• Loss: The company lost $57.3 million for the year ending March 31, 2026, compared to a $6.3 million loss in 2025.
• Core Performance: Their adjusted loss was $15.4 million in 2026, compared to a $0.7 million profit in 2025.
• Sales: Revenue fell to $180.2 million, a drop of $48 million (21.1%) from the previous year.
• Customer Trends: They gained 266,000 new customers in 2026, down from 351,000 in 2025. However, the average order value stayed steady at $98, up slightly from $97 the year before.

3. Major Wins and Challenges

• Strategic Partnerships: To compete in the pet care market, PetMeds partnered with Vetster for virtual vet visits and acquired PetCareRx to expand into food and supplies.
• The "Goodwill" Hit: A $27.3 million charge for "goodwill" drove much of the loss, reflecting a downward adjustment in the valuation of past acquisitions like PetCareRx.
• Operational Overhaul: The company is updating its systems, including a new ERP system and AI tools to personalize marketing.
• The "Affordability" Hurdle: With pet owners delaying vet care due to the economy, PetMeds is prioritizing private-label products, which offer higher profit margins and lower prices for budget-conscious shoppers.

4. Financial Health and Risks

• Dividends: The company stopped paying its quarterly dividend in February 2024 to preserve cash for technology and business growth.
• Accounting Weaknesses: The company identified "material weaknesses" in its financial reporting, indicating that their current systems for tracking money require improvement to ensure reporting accuracy.
• Supplier Reliance: 88% of inventory spending is concentrated among just ten suppliers, creating a dependency that could impact the company if these partners face disruptions or price hikes.
• Cybersecurity: As a digital-first retailer, the company faces ongoing risks related to data breaches, which could result in lost customer data, regulatory fines, and reputational damage.
• Tax Uncertainties: Increasing state-level scrutiny on sales tax collection for online retailers may lead to higher compliance costs and unexpected tax liabilities.

5. Future Outlook

The company is focused on increasing the lifetime value of each customer through a new loyalty program and call center automation to reduce overhead. They are also developing a "Pharmacy-as-a-Service" model, a business-to-business initiative where PetMeds manages shipping and logistics for other pet industry companies.

Investor Note: The company is in a "turnaround" phase. While they are actively modernizing their infrastructure, the combination of declining sales, significant losses, and identified weaknesses in financial reporting systems makes this a high-risk situation. Carefully weigh these operational hurdles against their potential for long-term growth in the subscription and B2B sectors.